Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40G78 | ISIN: US04522R3093 | Ticker-Symbol: N/A
NASDAQ
18.07.24
21:59 Uhr
0,600 US-Dollar
0,000
0,00 %
1-Jahres-Chart  (nicht börsennotiert)
ASLAN PHARMACEUTICALS LTD ADR Chart 1 Jahr

Aktuelle News zur ASLAN PHARMACEUTICALS

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.07.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation302Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore)...
► Artikel lesen
15.07.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal190SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ("ASLAN" or the "Company", Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing...
► Artikel lesen
ASLAN PHARMACEUTICALS Aktie jetzt für 0€ handeln
14.06.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change318SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ("ASLAN" or the "Company", Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing...
► Artikel lesen
02.05.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics338New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.The findings will...
► Artikel lesen
4 Nachrichten in den letzten 12 Monaten